Published in
Cell Press, Cancer Cell, 1(20), p. 119-131, 2011
DOI: 10.1016/j.ccr.2011.05.026
BASIC/TRANSLATIONAL - Hormones & Breast Cancer, p. P1-48-P1-48
DOI: 10.1210/endo-meetings.2011.part1.p3.p1-48
Links
- ORCID
- Cell Press
- Endocrine Society
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
,
Hallie Wimberly,
Shannon T. Bailey,
Yuuki Imai,
David L. Rimm,
X. Shirley Liu,
X. Shirley Liu,
Myles Brown
Full text: Download
Abstract
Endocrine therapies for breast cancer that target the estrogen receptor (ER) are ineffective in the 25%-30% of cases that are ER negative (ER-). Androgen receptor (AR) is expressed in 60%-70% of breast tumors, independent of ER status. How androgens and AR regulate breast cancer growth remains largely unknown. We find that AR is enriched in ER- breast tumors that overexpress HER2. Through analysis of the AR cistrome and androgen-regulated gene expression in ER-/HER2+ breast cancers we find that AR mediates ligand-dependent activation of Wnt and HER2 signaling pathways through direct transcriptional induction of WNT7B and HER3. Specific targeting of AR, Wnt or HER2 signaling impairs androgen-stimulated tumor cell growth suggesting potential therapeutic approaches for ER-/HER2+ breast cancers.